Investors / United States / RiverVest Venture Partners
RiverVest Venture Partners
Venture capital · St. Louis, MO, United States · North America
RiverVest Venture Partners is a venture capital firm that founds and leads financings for biopharma and medical device companies. It invests in products with a known path to clinical approval and works with entrepreneurs, investors and key opinion leaders to build companies.
Invests inHealthcare & Biotech
In its own wordsbiopharmamedical deviceslife scienceshealthcareclinical trials
Your fit with RiverVest Venture Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRiverVest Venture Partners lists 9 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Growth, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside Abingworth, Sanofi Ventures and U.S. Venture Partners.
Counts come from funding rounds that name RiverVest Venture Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundRiverVest Venture Partners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 33% |
| Growth | 67% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 19th | 9 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 93th | 22% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Abingworth | 2 |
| Sanofi Ventures | 2 |
| U.S. Venture Partners | 2 |
| Able Partners | 1 |
| Advent Life Sciences | 1 |
| Aisling Capital | 1 |
| Aphelion Capital | 1 |
| Asahi Kasei Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers9100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare RiverVest Venture Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with RiverVest Venture Partners| Date | Company | Stage |
|---|---|---|
| 24 Sept 2025 | Series B | |
| 16 Apr 2025 | Series C+ |
Round details for RiverVest Venture Partners
Amounts, full round histories and every co-investor in RiverVest Venture Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
9 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company develops allogeneic T-cell therapies for various indications, including T-cell cancers and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Biolinq develops and manufactures a fully autonomous, needle-free glucose sensor | Healthcare & Biotech | Portfolio page | ||
| Glycomine is developing replacement therapies for rare genetic diseases | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| InterVene develops medical devices to treat venous obstructions and related conditions. | Healthcare & Biotech | Portfolio page | ||
| MacroGenics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies to improve the lives of cancer patients. | Healthcare & Biotech | Portfolio page | ||
| Cardialen is developing a therapeutic modality for atrial fibrillation using controlled electrical stimulation | Healthcare & Biotech | Portfolio page | ||
| Sparrow Pharmaceuticals is developing targeted cardiometabolic therapeutics | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Spruce Biosciences develops and commercializes novel therapies for neurological and endocrine disorders with significant unmet medical need | Healthcare & Biotech | Portfolio page | ||
| Standard Bariatrics produces medical devices, such as staplers, for bariatric surgery procedures. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- rivervest.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Apr 2025
- Companies checked
- 9
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get RiverVest Venture Partners' profile as data
Pull RiverVest Venture Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/rivervest.com
# also
GET /v1/firms/rivervest.com/portfolio
GET /v1/firms/rivervest.com/coinvestors
GET /v1/firms/rivervest.com/news